A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

6533b831fe1ef96bd12990ad

RESEARCH PRODUCT

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

Domenica Matranga Giuseppe Fasolino Salvatore Cillino Maria Vadalà Costantino John Trombetta Giuseppe De Crecchio Paolo Milani Alfredo Pece Carla Monteleone

subject

Male Vascular Endothelial Growth Factor A Visual Acuity/drug effects Visual acuity genetic structures Visual Acuity Angiogenesis Inhibitors law.invention Bevacizumab/therapeutic use 0302 clinical medicine Randomized controlled trial law Myopia Medicine Prospective Studies Prospective cohort study Pathological myopia Aged 80 and over Middle Aged Sensory Systems Bevacizumab Vascular endothelial growth factor A Choroidal neovascularization Intravitreal Injections Myopia Degenerative Female medicine.symptom medicine.drug Adult medicine.medical_specialty Bevacizumab Neuroscience(all)CNV Bevacizumab; CNV; Pathological myopia; Ranibizumab.Antibodies Monoclonal Humanized Ranibizumab/therapeutic use 03 medical and health sciences Cellular and Molecular Neuroscience Ophthalmology Ranibizumab Vascular Endothelial Growth Factor A/antagonists & inhibitors Humans Angiogenesis Inhibitors/therapeutic use Intravitreal bevacizumab Aged pathological myopia CNV bevacizumab ranibizumab Settore MED/30 - Malattie Apparato Visivo business.industry Therapeutic effect Choroidal Neovascularization/drug therapy eye diseases Choroidal Neovascularization Ophthalmology Regimen 030221 ophthalmology & optometry Myopia Degenerative/drug therapy sense organs Ranibizumab business 030217 neurology & neurosurgery Follow-Up Studies

description

AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM). METHODS: This was a prospective multicenter randomized nonblinded trial. RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was 0.52 logMAR (20/63 Seq) and 54 ls, and final BCVA was 0.51 logMar (20/63 Seq) and 57 ls. In group R, mean basal BCVA was 0.62 logMAR (20/80 Seq) and 45 ls, and the final values were 0.50 logMAR (20/63 Seq) and 58 ls. Statistical comparison of the two groups showed no significant difference (logMAR p = 0.90 and letters p = 0.78). Multivariate analysis showed no influence of age or previous photodynamic treatment (PDT) on final visual changes. The mean number of treatments in the first year was 2.7 in group B and 2.3 in group R (p = 0.09). CONCLUSION: Myopic CNV equally benefits from on-demand intravitreal injection of either bevacizumab or ranibizumab; the therapeutic effect is independent of previous PDT and age.

year	journal	country	edition	language
2014-08-20	Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

10.1007/s00417-014-2886-x https://pubmed.ncbi.nlm.nih.gov/26858244